New Zealand markets closed

ABBV Mar 2024 190.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
12.970.00 (0.00%)
As of 02:46PM EST. Market open.
Full screen
Previous close12.97
Open14.10
Bid0.00
Ask0.00
Strike190.00
Expiry date2024-03-15
Day's range12.97 - 14.10
Contract rangeN/A
Volume3
Open interestN/A
  • Bloomberg

    AbbVie Sells $15 Billion of Bonds to Buy ImmunoGen, Cerevel

    (Bloomberg) -- Pharmaceutical giant AbbVie Inc. sold $15 billion of bonds in the US investment-grade market on Thursday to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., adding to a recent rush of buyout financings. Most Read from BloombergNvidia Rises Most in About Nine Months as AI Drives SalesT-Bills Without Tax Bills? This Fund Says It Cracked the CodeStocks Rally as AI Craze Sweeps Across the World: Markets WrapAT&T Outage Triggered by Company Work on N

  • PR Newswire

    AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology

    AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. The collaboration will integrate AbbVie's expertise in oncology and immunology with Tentarix's proprietary Tentacles™ platform.

  • Reuters

    UPDATE 1-AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports

    AbbVie is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics, Bloomberg News reported on Wednesday, citing people with knowledge of the matter. AbbVie did not immediately respond to Reuters' request for a comment. In December, AbbVie announced back-to-back acquisitions - a $8.7 billion plan to buy Cerevel and its $10.1 billion deal for ImmunoGen, which was recently completed.